Gene Arrays

Welcome to the “Gene Arrays” Genome and Microarray facilities. Our arrays carried out at certified labs in New York, NY, USA. Gene Arrays specialized in the area of genome sequencing using various instruments (Illumina HiSeq 2500, Illumina MiSeq, Ion Torrent and Pacific Biosciences) and microarrays carried out Affymetrix and Illumina platforms and also Library preparation for NGS including miRNA extractions. Bioinformatic Support: NGS data analysis, ChIP-Seq, RNA-Seq, DNA methylation, Microarray analysis for Gene Expression Profiling (GEP), and Pathway analysis

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDICAL

TRIALSPARK, COMMITTS TO IMPROVE SPEED, QUALITY, AND INNOVATION OF CLINICAL TRIALS, ANNOUNCES COLLABORATION WITH ADITUM BIO

TrialSpark | December 21, 2020

news image

TrialSpark, a tech-enabled drug development accomplice focused on improving the speed, quality, and innovation of clinical trials, officially announces a collaboration with Aditum Bio, a San Francisco-based venture endeavor firm engaged with respect to getting and creating biotechnology resources that will benefit patients. Anteris Bio in-licensed ANT-401 from vTv Therapeutics, to be studied in CKD and across multiple etiologies of renal diseases. As Aditum Bio's drug developm...

Read More

ARCTIC VISION ANNOUNCES US$32MN IN SERIES A TO EXPAND INNOVATIVE PRODUCT PORTFOLIO IN OPHTHALMOLOGY

Arctic Vision | July 15, 2020

news image

Arctic Vision, a clinical-stage biotechnology company incubated by Nan Fung Life Sciences and Pivotal BioVenture Partners China in 2019, today announced its $32mn Series A financing led by Morningside Ventures, together with its existing investors. Arctic Vision focuses on the development and commercialization of innovative ophthalmology therapies in China and Asia. The three investment institutions are actively investing in leading life science companies in the world with long term commitment.&...

Read More

CELL AND GENE THERAPY

BRAZIL’S SENAI CIMATEC DOSES FIRST HEALTHY VOLUNTEERS IN PHASE 1 TRIAL OF HDT BIO’S RNA COVID-19 VACCINE

HDT Bio Corp. | January 17, 2022

news image

HDT Bio Corp., a U.S. developer of immunotherapies for oncology and infectious diseases and SENAI CIMATEC, an important Brazilian education, research, and innovation institute, have dosed the first healthy volunteers in Brazil in a Phase 1 trial of HDT Bio’s RNA COVID-19 vaccine, HDT-301. SENAI CIMATEC will conduct the clinical trial under the name Vaccine RNA MCTI-CIMATEC-HDT. The vaccine uses HDT Bio’s proprietary lipid nanoparticle RNA-delivery technology. Read More

INDUSTRIAL IMPACT

BIOAUXILIUM RESEARCH EXPANDS ITS NO-WASH THUNDER™ TR-FRET CELL SIGNALING ASSAY PORTFOLIO

BioAuxilium Research Inc. | February 10, 2022

news image

At the annual Society for Laboratory Automation and Screening International Conference and Exhibition in Boston, BioAuxilium Research Inc., a biotech tool company focused on facilitating access to fully validated assay kits to the biomedical research community, today announced the expansion of its no-wash THUNDER™ time-resolved Förster resonance energy transfer technology portfolio by introducing new cell signaling pathway and biomarker research assay kits, along with a panel of &ldqu...

Read More
news image

MEDICAL

TRIALSPARK, COMMITTS TO IMPROVE SPEED, QUALITY, AND INNOVATION OF CLINICAL TRIALS, ANNOUNCES COLLABORATION WITH ADITUM BIO

TrialSpark | December 21, 2020

TrialSpark, a tech-enabled drug development accomplice focused on improving the speed, quality, and innovation of clinical trials, officially announces a collaboration with Aditum Bio, a San Francisco-based venture endeavor firm engaged with respect to getting and creating biotechnology resources that will benefit patients. Anteris Bio in-licensed ANT-401 from vTv Therapeutics, to be studied in CKD and across multiple etiologies of renal diseases. As Aditum Bio's drug developm...

Read More
news image

ARCTIC VISION ANNOUNCES US$32MN IN SERIES A TO EXPAND INNOVATIVE PRODUCT PORTFOLIO IN OPHTHALMOLOGY

Arctic Vision | July 15, 2020

Arctic Vision, a clinical-stage biotechnology company incubated by Nan Fung Life Sciences and Pivotal BioVenture Partners China in 2019, today announced its $32mn Series A financing led by Morningside Ventures, together with its existing investors. Arctic Vision focuses on the development and commercialization of innovative ophthalmology therapies in China and Asia. The three investment institutions are actively investing in leading life science companies in the world with long term commitment.&...

Read More
news image

CELL AND GENE THERAPY

BRAZIL’S SENAI CIMATEC DOSES FIRST HEALTHY VOLUNTEERS IN PHASE 1 TRIAL OF HDT BIO’S RNA COVID-19 VACCINE

HDT Bio Corp. | January 17, 2022

HDT Bio Corp., a U.S. developer of immunotherapies for oncology and infectious diseases and SENAI CIMATEC, an important Brazilian education, research, and innovation institute, have dosed the first healthy volunteers in Brazil in a Phase 1 trial of HDT Bio’s RNA COVID-19 vaccine, HDT-301. SENAI CIMATEC will conduct the clinical trial under the name Vaccine RNA MCTI-CIMATEC-HDT. The vaccine uses HDT Bio’s proprietary lipid nanoparticle RNA-delivery technology. Read More

news image

INDUSTRIAL IMPACT

BIOAUXILIUM RESEARCH EXPANDS ITS NO-WASH THUNDER™ TR-FRET CELL SIGNALING ASSAY PORTFOLIO

BioAuxilium Research Inc. | February 10, 2022

At the annual Society for Laboratory Automation and Screening International Conference and Exhibition in Boston, BioAuxilium Research Inc., a biotech tool company focused on facilitating access to fully validated assay kits to the biomedical research community, today announced the expansion of its no-wash THUNDER™ time-resolved Förster resonance energy transfer technology portfolio by introducing new cell signaling pathway and biomarker research assay kits, along with a panel of &ldqu...

Read More